clinical trial · NCT06356129
Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma
Celgene·phase3·active not recruiting·n = 850
Large B-cell LymphomaGolcadomidePlaceboRituximabCyclophosphamideDoxorubicinVincristinePrednisone
brief summary
The purpose of this study is to compare the effectiveness and safety of golcadomide in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) chemotherapy vs placebo in combination with R-CHOP chemotherapy in participants with previously untreated high-risk large B-cell lymphoma (LBCL).
started
Jun 19, 2024
primary completion
Aug 14, 2028
completion
Nov 20, 2029
last updated
Feb 12, 2026
official title
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Comparing the Efficacy and Safety of Golcadomide Plus R-CHOP Chemotherapy vs Placebo Plus R-CHOP Chemotherapy in Participants With Previously Untreated High-risk Large B-cell Lymphoma (GOLSEEK-1)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol